ClinicalTrials.gg
RecruitingNCT07278089SAFE-ECHOUpdated Dec 11, 2025

AF Screening in Patients With Abnormal Echocardiographic Parameters

An interventional study of study arm in Atrial Fibrillation (AF), sponsored by Tze-Fan Chao. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Tze-Fan Chao · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Mar 2025, registered Nov 2025).
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,000
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 95 studies in Atrial Fibrillation with a site in Taiwan — 17 open to participants now, 25 under way, 3 of them phase 3. Atrial Fibrillation · Taiwan.

Planned enrollment
19th of 67
3,000 · median 448
Started
2025
with 8 others
No phase
34 of 95
12 open now
Primary completion
2031-12
later than 24 of 24 live
Registered
85th of 95
by date

Among the 95 studies in Atrial Fibrillation with a site in Taiwan, this one is the 19th largest by planned enrollment of the 67 interventional ones that give a count, is one of 9 that started in 2025, is one of 34 with no phase, reaches primary completion later than 24 of the 24 other live ones, and was the 85th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

17 of the 95 studies in Atrial Fibrillation with a site in Taiwan are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Atrial Fibrillation with a site in Taiwan, or all of them as a file.
02

Study summary

To evaluate the feasibility of specific echocardiographic parameters as criteria for AF screening and to determine the AF detection yield of scheduled extended ECG monitoring compared to contemporary care.

03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: patients who met any of the following criteria

  1. LAE: defined as LAD ≥ 45 mm or LAVI > 34 ml/m2;
  2. LVH: defined as LV septal or posterior wall thickness ≥ 15 mm;
  3. E/e' > 14;
  4. grade II or III diastolic dysfunction;
  5. VHD;
  6. HF: defined as \< 40% or LVEF ≥40% with clinical presentation compatible with Framingham criteria, functional classification II-IV, and N-terminal pro-B type natriuretic peptide (NT-proBNP) > 125 pg/ml.

Exclusion Criteria:

  • Patients with a history of AF or atrial flutter, congenital heart disease, acute coronary syndrome undergoing urgent percutaneous coronary intervention within 3 months, uncontrolled hyperthyroidism, end-stage renal disease, unstable hemodynamic status or any known major comorbidities or medical conditions with expected less than 1 year are excluded.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,000 participants (estimated)

Study arms

  • Active comparator
    study arm

    Diagnostic Test: study arm

  • No intervention
    control arm

Interventions

  • Diagnostic teststudy arm

    Scheduled cardiac rhythm monitoring every 3 months using extended continuous ECG monitoring

06

What researchers measure

Primary outcomes

  1. the detection of AF either by 12-lead ECG or any episodes of AF lasting ≥ 30 seconds by the single-lead ECG or 7-day continuous recording.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Liao JN, Kuo L, Liu CM, Tsai CT, Chang HC, Hung CL, Chao TF, Yu WC. Screening of Atrial Fibrillation/Arrhythmia Events in Patients With Abnormal ECHOcardiographic Parameters: The Randomized, Prospective SAFE-ECHO Study Design and Rationale. Am J Cardiol. 2026 Jul 1;270:97-104. doi: 10.1016/j.amjcard.2026.03.074. Epub 2026 Apr 16. PubMed 41999845 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2031, 81 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 81 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2025
First posted
Dec 11, 2025
StartActual
Mar 17, 2025
Primary completionEst.
Dec 31, 2031
CompletionEst.
Dec 31, 2032
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07278089
Lead sponsor
Tze-Fan Chao
Responsible party
Tze-Fan Chao (Doctor, Taipei Veterans General Hospital, Taiwan) — Sponsor-investigator
First posted
Dec 11, 2025
Start date
Mar 17, 2025
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Dec 11, 2025

Study contacts

Tze-Fan Chao, PhD
Contact
eyckeyck@gmail.com
886-2-28727794

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion